Atopic dermatitis biomarkers and precision medicine — the development of serum, genetic, and microbiome biomarkers enabling AD patient stratification, treatment selection, and treatment response prediction — represents the AD field's movement toward precision dermatology, with the Atopic Dermatitis Market reflecting biomarker development as a clinical and commercial market driver.

TARC/CCL17 as AD activity biomarker — thymus and activation-regulated chemokine (TARC/CCL17) elevated in AD and correlating with disease severity representing a quantitative blood biomarker for disease activity monitoring that could supplement or complement clinical scoring tools like EASI, IGA, and SCORAD. TARC's correlation with dupilumab treatment response and potential as a treatment monitoring biomarker has been investigated in clinical trial analyses.

Type 2 biomarker profiling for biologic selection — the use of serum IgE, blood eosinophil count, TARC/CCL17, and skin tape strip cytokine profiling to identify patients with high type 2 inflammation predicting superior response to IL-4/IL-13 biologics — represents the precision medicine approach to AD treatment selection that is still primarily in research phase but advancing toward clinical application. Patients with very high IgE, eosinophilia, and TARC may particularly benefit from type 2-targeted therapy while patients with mixed inflammatory profiles may require different approaches.

Filaggrin mutation genetic testing — the FLG loss-of-function mutations most strongly associated with AD susceptibility affecting approximately fifty percent of European AD patients — provides genetic risk information that can identify AD patients with the primary skin barrier defect underlying their disease. FLG mutation carriers have the most severe, persistent AD with high rates of atopic comorbidities suggesting that FLG-based patient stratification may inform long-term treatment planning and preventive intervention.

Do you think the AD field will eventually have validated predictive biomarkers guiding biologic therapy selection that enable personalized treatment choices beyond empiric trial-and-error?

FAQ

What is the EASI score for atopic dermatitis? EASI (Eczema Area and Severity Index) is the most commonly used AD clinical outcome measure in clinical trials; evaluates four body regions (head/neck, trunk, upper extremities, lower extremities) for erythema, induration/papulation, excoriation, and lichenification on 0-3 scale; area involvement estimated and combined with severity scores for total 0-72 points; EASI-50, EASI-75, and EASI-90 measure proportion of patients achieving fifty, seventy-five, or ninety percent improvement from baseline; EASI-75 (seventy-five percent improvement) is the standard primary endpoint in AD clinical trials; EASI validated for all ages including infants.

What are the key filaggrin mutations in atopic dermatitis? FLG (filaggrin) gene encodes the skin barrier protein filaggrin essential for cornified cell envelope formation and natural moisturizing factor production; R501X and 2282del4 are the two most common European FLG null mutations each with population frequency approximately four percent; compound heterozygotes (one copy each) have lower filaggrin expression than homozygotes; FLG mutations are highly penetrant for AD (approximately sixty percent of FLG null mutation carriers develop AD) but many AD cases lack FLG mutations; FLG mutations are risk factors not absolute disease determinants; Asian populations have different FLG mutations (3321delA, 442del11) with similar phenotypic effects.

#AtopicDermatitis #ADbiomarker #PrecisionDermatology #FilaggrinMutation #EASIscore #TARCbiomarker